Showing results (101-110 of 126) with videos related to

Sort By:
Pageof 13
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Advances|July 25, 2018
The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Theo de Witte, et al.
The Journal of Experimental Medicine|July 27, 2016
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic miceMohamed-Amine Hamouda, Arnaud Jacquel, Guillaume Robert, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective StudyMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood|May 13, 2026
Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST StudyNicolas Boissel, Françoise Huguet, Thibaut Tl Leguay, et al.
The Lancet. Haematology|June 18, 2025
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trialElias Jabbour, Federico Lussana, Pilar Martínez-Sánchez, et al.
Eclinicalmedicine|September 1, 2023
Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trialFlorent Malard, Michael Loschi, Anne Huynh, et al.
Blood Cancer Discovery|February 11, 2026
Prognostic Model Combining Mutational and Cytogenetic Profiles in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating AgentsDimitrios Drekolias, Fatima Tuz Zahra, Caroline Fileni, et al.
Cancer Discovery|August 23, 2020
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Frank Ling, Camille Vaganay, et al.
Blood Advances|September 9, 2025
Allogeneic hematopoietic stem cell transplantation in patients with germ line DDX41 mutated myeloid malignanciesMichael Loschi, Marie-Charlotte Villy, Jacques-Emmanuel Galimard, et al.
Pageof 13